8-K filing — Edesa Biotech, Inc. (EDSA)
Filed: 2026-10-15 AccNo: 0001171843-26-006647 Size: 233 KB Item 8.01: Other Events
Stocks · News reference
Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Edesa Biotech shares are trading lower after the company announced the pricing of its $25 million proposed public offering of 3,870,500 shares and warrants at a $5.50 combined price.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out yesterday.